chr15-89317469-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_002693.3(POLG):c.3550G>A(p.Asp1184Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000248 in 1,613,976 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
POLG
NM_002693.3 missense
NM_002693.3 missense
Scores
11
7
1
Clinical Significance
Conservation
PhyloP100: 7.57
Genes affected
POLG (HGNC:9179): (DNA polymerase gamma, catalytic subunit) Mitochondrial DNA polymerase is heterotrimeric, consisting of a homodimer of accessory subunits plus a catalytic subunit. The protein encoded by this gene is the catalytic subunit of mitochondrial DNA polymerase. The encoded protein contains a polyglutamine tract near its N-terminus that may be polymorphic. Defects in this gene are a cause of progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.979
PP5
Variant 15-89317469-C-T is Pathogenic according to our data. Variant chr15-89317469-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 426100.Status of the report is reviewed_by_expert_panel, 3 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLG | NM_002693.3 | c.3550G>A | p.Asp1184Asn | missense_variant | 22/23 | ENST00000268124.11 | NP_002684.1 | |
POLG | NM_001126131.2 | c.3550G>A | p.Asp1184Asn | missense_variant | 22/23 | NP_001119603.1 | ||
POLGARF | NM_001406557.1 | c.*2822G>A | 3_prime_UTR_variant | 22/23 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLG | ENST00000268124.11 | c.3550G>A | p.Asp1184Asn | missense_variant | 22/23 | 1 | NM_002693.3 | ENSP00000268124.5 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152152Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152152
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251494Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135920
GnomAD3 exomes
AF:
AC:
2
AN:
251494
Hom.:
AF XY:
AC XY:
1
AN XY:
135920
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461824Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 727210
GnomAD4 exome
AF:
AC:
2
AN:
1461824
Hom.:
Cov.:
31
AF XY:
AC XY:
0
AN XY:
727210
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152152Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74336
GnomAD4 genome
AF:
AC:
2
AN:
152152
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74336
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Mitochondrial disease Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Wellcome Centre for Mitochondrial Research, Newcastle University | Apr 07, 2017 | - - |
Pathogenic, reviewed by expert panel | curation | ClinGen Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel, ClinGen | May 23, 2021 | The c.3550 G>A (p.Asp1184Asn) variant in POLG has been reported in gnomAD in 0.0001% allele frequency with no homozygotes (PM2). There is also multiple other pathogenic variants at the same amino acid residue as well as nearby: Asp1184His, Ile1185Thr, Ile1185Asn, Asp1186His, and Cys1188Arg all have been reported in the Human Gene Mutation Database in association with POLG-related disorders (PS1; PMID 24077912). There are 5 cases reported with POLG related disease symptoms PEO, neurological phenotype, liver issues, and epilepsy. These cases are reported in 2 compound heterozygotes with c.679 C>T; p.Arg227Trp, a compound heterozygote with c.752 C>T; p.Thr251Ile and c.1759 C>T; p.Pro587Leu; a compound heterozygote with c.3285 C>G; p.Ser1095Arg (PM3_strong; PMID:16957900; PMID:30678510; PMID:19344718; PMID:19578034).There is 1 additional case in the literature as a compound heterozygotes however there is conflicting evidence of pathogenicity of the variant. Therefore this case could not be counted (PMID: 16401742). In summary, this variant meets criteria to be classified as pathogenic for mitochondrial disease inherited in an autosomal recessive manner. ntDNA ACMG/AMP criteria for POLG applied: PS1, PM2, PM3_strong - |
Progressive sclerosing poliodystrophy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | May 06, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 27, 2023 | ClinVar contains an entry for this variant (Variation ID: 426100). This missense change has been observed in individuals with autosomal recessive POLG-related disorders (PMID: 16401742, 16957900, 19578034, 30678510). It has also been observed to segregate with disease in related individuals. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 1184 of the POLG protein (p.Asp1184Asn). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt POLG protein function. For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects POLG function (PMID: 20185557). - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 27, 2021 | The c.3550G>A (p.D1184N) alteration is located in exon 22 (coding exon 21) of the POLG gene. This alteration results from a G to A substitution at nucleotide position 3550, causing the aspartic acid (D) at amino acid position 1184 to be replaced by an asparagine (N). Based on data from the Genome Aggregation Database (gnomAD) database, the POLG c.3550G>A alteration was observed in 0.001% (3/282,882) of total alleles studied, with a frequency of 0.003% (1/35,440) in the Latino subpopulation. This alteration has been previously reported in multiple patients with autosomal recessive POLG-related mitochondrial disorders, including progressive external ophthalmoplegia (arPEO) (Gonzalez-Vioque, 2006; de Vries, 2007; Blok, 2009; Li, 2019). This amino acid position is highly conserved in available vertebrate species. Functional studies using yeast mtDNA point mutagenesis with p.D1184N (yeast ortholog D941N) showed an increased petite colony formation frequency and exhibited decreased mtDNA copy number, suggesting that mtDNA depletion is a major phenotype of this disease-associated mutant (Stumpf, 2010). The in silico prediction for the p.D1184N alteration is inconclusive. Based on the available evidence, this alteration is classified as likely pathogenic. - |
POLG-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 18, 2024 | The POLG c.3550G>A variant is predicted to result in the amino acid substitution p.Asp1184Asn. This variant was reported in the compound heterozygous state in individuals with autosomal recessive progressive external ophthalmoplegia (Blok et al. 2009. PubMed ID: 19578034; Gonzalez-Vioque et al. 2006. PubMed ID: 16401742; Li et al. 2019. PubMed ID: 30678510). This variant affects a highly conserved residue in the polymerase domain in mitochondrial polymerase gamma. In addition, another variant affecting the asparagine 1184 residue has also been reported to cause autosomal recessive PEO when present in trans with a second pathogenic variant (Martikainen et al. 2010. PubMed ID: 22778364). Heterozygous carriers of the POLG c.3550G>A variant have been reported to be asymptomatic (Blok et al. 2009. PubMed ID: 19578034; Li et al. 2019. PubMed ID: 30678510). This variant is reported in 0.0028% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/15-89860700-C-T). Taken together, this variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 31, 2018 | The D1184N variant in the POLG gene has been reported previously in multiple unrelated individuals with POLG-related disorders who had a second POLG variant identified (de Vries et al., 2007; Amiot et al., 2009; Blok et al., 2009). Functional studies show that D1184N results in mtDNA depletion as well as increased petite colony formation, suggesting it may be a null variant (Stumpf et al., 2010). The D1184N variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The D1184N variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species, and a different missense variant in the same residue (D1184H) as well as missense variants in nearby residues (I1185T, I1185N, D1186H, C1188R) have been reported in the Human Gene Mutation Database in association with POLG-related disorders (Stenson et al., 2014), supporting the functional importance of this region of the protein. Therefore, D1184N is considered a pathogenic variant. - |
Progressive sclerosing poliodystrophy;C1834846:Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1;C1843851:Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis;C3150914:Mitochondrial DNA depletion syndrome 4b;C4225153:Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 10, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
.;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M;M
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D
REVEL
Pathogenic
Sift
Uncertain
D;D
Sift4G
Uncertain
D;D
Polyphen
D;D
Vest4
MutPred
Loss of helix (P = 0.1706);Loss of helix (P = 0.1706);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at